Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation, and Management
Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit
This program highlights the burden of cardiovascular disease in high-risk patients, focusing on the association between LDL- C and ASCVD risk and the importance of lowering LDL-C levels. The use of LDL-C– lowering therapies to reduce risk in high-risk patients, such as patients with diabetes, is described with considerations from the current environment.
This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content.